Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARQ-234 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| ARQ-234 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ARQ-234 | BIOLOGICAL | ARQ-234 subcutaneous injectable solution |
| Placebo | DRUG | Placebo subcutaneous injectable solution |
Inclusion Criteria (All Participants): * Able and willing to provide written informed consent. * Adults 18-65 years (inclusive) at consent. * Generally healthy at screening/baseline (no clinically significant findings on medical history, exam, vitals, ECG, or safety labs, per investigator). * Contr...
Top 20 of 25 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 9 | PHASE3 | Upadacitinib, Lutikizumab |
| Pfizer Inc. | PFE | 10 | PHASE3 | Abrocitinib, PF-08049820, PF-07275315, PF-07264660, PF-07832837 |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Lebrikizumab |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab, Dupilumab SAR231893, Dupilumab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | dupilumab, REGN20423 |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777, APG990 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632, GHZ339 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | Bempikibart |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE1 | ARQ-234 |
| Generate Biomedicines, Inc. | GENB | 1 | PHASE1 | GB-7624 |
ARQ-234 is an investigational monoclonal antibody being developed for the treatment of Atopic Dermatitis (AD), also known as eczema. It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being studied in patients with this condition to evaluate its safety and efficacy.
ARQ-234 targets CD200R, a receptor involved in immune regulation. By binding to this receptor, the monoclonal antibody aims to modulate immune responses that contribute to Atopic Dermatitis. This mechanism is being investigated in early-stage clinical trials to understand its potential therapeutic effect.
ARQ-234 is being developed by Arcutis Biotherapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker ARQT. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Atopic Dermatitis.
ARQ-234 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1a/1b study is recruiting participants to assess the drug's safety, tolerability, and pharmacokinetics in healthy volunteers and patients with Atopic Dermatitis.
ARQ-234 is being studied in a Phase 1a/1b clinical trial registered as NCT07453602. This randomized, double-blind, placebo-controlled study is evaluating single ascending doses and multiple ascending doses of ARQ-234. The trial is recruiting 125 participants in the United States, including healthy volunteers and individuals with Atopic Dermatitis.
ARQ-234 is a unique investigational monoclonal antibody and is not known to be the same as any other approved or marketed drug. It is being developed specifically for Atopic Dermatitis and is currently in early-stage clinical trials to determine its safety and potential efficacy.